These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1424 related articles for article (PubMed ID: 29730801)
1. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Jindal V; Arora E; Gupta S Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801 [TBL] [Abstract][Full Text] [Related]
2. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer. Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744 [TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice. Jindal V; Arora E; Masab M; Gupta S Med Oncol; 2018 May; 35(6):84. PubMed ID: 29728788 [TBL] [Abstract][Full Text] [Related]
4. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525 [TBL] [Abstract][Full Text] [Related]
5. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A Front Immunol; 2018; 9():1717. PubMed ID: 30108584 [TBL] [Abstract][Full Text] [Related]
6. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. Di S; Li Z Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709 [TBL] [Abstract][Full Text] [Related]
7. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Zhang E; Gu J; Xu H Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591 [TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
9. Establishing guidelines for CAR-T cells: challenges and considerations. Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523 [TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor transduced T cells: Tuning up for the next generation. Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551 [TBL] [Abstract][Full Text] [Related]
11. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies. Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150 [TBL] [Abstract][Full Text] [Related]
12. CAR T Cell Therapy for Solid Tumors. Newick K; O'Brien S; Moon E; Albelda SM Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544 [TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
14. Engineering CAR-T Cells for Improved Function Against Solid Tumors. Morgan MA; Schambach A Front Immunol; 2018; 9():2493. PubMed ID: 30420856 [TBL] [Abstract][Full Text] [Related]
15. Making CAR T Cells a Solid Option for Solid Tumors. Schmidts A; Maus MV Front Immunol; 2018; 9():2593. PubMed ID: 30467505 [TBL] [Abstract][Full Text] [Related]
16. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. Lin C; Zhang J Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229 [TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cells: a novel therapy for solid tumors. Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156 [TBL] [Abstract][Full Text] [Related]
18. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors. Jin C; Yu D; Essand M Immunotherapy; 2016 Dec; 8(12):1355-1361. PubMed ID: 28000533 [TBL] [Abstract][Full Text] [Related]
19. CARTs for Solid Tumors: Feasible or Infeasible? Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706 [TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers. Chen L; Qiao D; Wang J; Tian G; Wang M Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]